48 results
8-K
MIRA
Mira Pharmaceuticals Inc
28 Jun 24
Departure of Directors or Certain Officers
5:00pm
Report on Form 8-K. The description of such agreement contained herein is summary in nature and is qualified in its entirety by reference to the full
8-K
EX-10.1
MIRA
Mira Pharmaceuticals Inc
28 Jun 24
Departure of Directors or Certain Officers
5:00pm
subsequent act or omission of a substantially similar nature or type, or (vi) Employee’s material non-compliance with the terms of this Agreement or any … involvement with the Company, Employee will promptly deliver to the Company all documents and materials of any nature pertaining to Employee’s work
10-K
2023 FY
MIRA
Mira Pharmaceuticals Inc
1 Apr 24
Annual report
7:00am
.
Prioritize safety and efficacy, given the complex nature of PTSD and potential comorbidities.
In summary, the clinical development plan for Ketamir … trial enrollment and expenses;
research and development expenses; and
the timing and nature of contract manufacturing and contract research payments
8-K
EX-10.1
kkye1sewh
20 Nov 23
MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2
8:10am
8-K
EX-10.2
d7yh0bcj4mvh
20 Nov 23
MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2
8:10am
10-Q
ym8nazlm
15 Sep 23
Quarterly report
4:45pm
8-K
1oiw4ppf2ektkw7tt80e
31 Aug 23
Departure of Directors or Certain Officers
5:27pm
8-K
EX-1.1
lqlisokvrjuwynamz
7 Aug 23
MIRA Pharmaceuticals, Inc. Announces Pricing of $8.9 Million Initial
5:14pm
424B4
wis50u83d2qyx67ik09
4 Aug 23
Prospectus supplement with pricing info
1:01pm
424B1
zacu7brh5i
4 Aug 23
Prospectus with pricing info
12:59pm